- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07355387
Home Based Functional Balance Intervention for Multiple Sclerosis (HomeFBIinMS)
Home Based Functional Balance Intervention (FBI) for Physical and Cognitive Symptoms of Multiple Sclerosis
The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS).
Combined Specific Aims:
Aim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group).
Hypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group.
Aim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program.
Hypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group.
Aim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life).
Hypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group.
All assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy.
The investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.
Study Overview
Status
Conditions
Detailed Description
This project investigates the feasibility of a remote, home-based Functional Balance Intervention (FBI) targeting the physical and cognitive symptoms of multiple sclerosis (MS).
The study is a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of the FBI on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Because the exercise training will be completed independently at home, additional precautionary measures for participant safety (such as requiring a Helper Buddy) and modified home evaluations will be implemented to monitor training progression.
A total of 75 people with multiple sclerosis (PwMS) will be recruited and undergo a telephone screening. Accounting for an estimated 20% screening failure rate, the investigators expect to enroll approximately 60 PwMS in the project. Based on an additional 20% expected attrition following the initial screening, approximately 48 PwMS are anticipated to be eligible for participation. Eligible participants will complete one pre-training assessment session before being randomized into one of two groups: the FBI (Intervention Group) or the Stretching (Control) group.
Following randomization, each participant and their designated Helper Buddy will complete an onboarding session that provides detailed instructions regarding assessment procedures and training logistics. Participants will then engage in independent training sessions with their Helper Buddy twice per week for four months. Given the expected 15-17% attrition rate based on prior experience, the target final sample size is 40 PwMS. The investigators expect 40 participants to complete post-training assessments after four months and finish the study.
All assessment sessions will be conducted virtually via Zoom. Measures collected during the initial screening, pre-training assessment, training progression checks, and post-training assessment will occur either via Zoom with a Helper Buddy present or through survey links distributed via the University of Illinois REDCap system. Training sessions will be performed independently by participants in the presence of their Helper Buddy.
The overall goal of this project is to determine the feasibility of the FBI and evaluate its impact on physical and cognitive functions, as well as other measures of daily living among PwMS in a home-based environment. This protocol builds on strong evidence from previous successful trials involving neurological populations. It has been piloted in a laboratory setting with individuals with stroke and mild cognitive impairment, demonstrating both safety and efficacy. In addition, it has been tested in telerehabilitation formats among healthy older adults and frail older individuals, with results indicating feasibility, safety, and effectiveness for independent home exercise and no reported adverse events.
The investigators now intend to translate this evidence-based protocol to examine its effects in people with multiple sclerosis. If successful, this study could have substantial impact by providing a low-cost, safe, and effective intervention that increases accessibility for rural and underserved populations.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tanvi Bhatt, PhD
- Phone Number: 3124139772
- Email: tbhhat6@uic.edu
Study Contact Backup
- Name: Rudri Purohit, PhD
- Phone Number: 3128773640
- Email: rpuroh2@uic.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- University of Illinois at Chicago
-
Contact:
- Tanvi Bhatt, PhD
- Phone Number: 3128773640
- Email: rpuroh2@uic.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
Telephone Screening Inclusion Criteria:
- Age 40-90 years.
- Self-reported diagnosis of Multiple Sclerosis.
- On stable disease-modifying therapy for ≥6 months.
- No PT/OT balance-related therapy in the past 6 months.
- Able to stand from a chair independently (with or without hand support).
- Score 25-75% on the 12-item MS Walking Scale.
- No other neurological, cardiopulmonary, musculoskeletal, or systemic conditions affecting standing/walking.
- English speaking.
- Willing to complete all study procedures including Zoom sessions.
- Has reliable internet access.
- Has a helper buddy available for all sessions.
- Possible mild cognitive impairment based on self-report.
Initial Screening Inclusion Criteria:
- Moderate disability: ePR-EDSS score 4.0-6.5.
- Mild cognitive impairment: MoCA 18-25, or Jak/Bondi criteria for those scoring 26-30.
- Physically inactive or moderately active (Godin score <24).
- Cardiovascular safety parameters within acceptable limits.
- No global aphasia (Mississippi Aphasia Screening Test ≥71 percent).
- Berg Balance Scale score ≥40/56.
- Able to walk 1 block with or without an assistive device.
Helper Buddy Inclusion Criteria:
- Age ≥18 years.
- Lives within close proximity to the participant.
- No self-reported major medical conditions limiting safety assistance.
- English speaking.
- Able to attend all training and assessment sessions.
- Able to assist with basic safety, positioning, and communication with the research team.
- Has internet access and can use Zoom.
Exclusion Criteria
Telephone Screening Exclusion Criteria:
- MS relapse or exacerbation within the past 3 months.
- Recent major surgery (<6 months) or hospitalization (<3 months).
- Resting shortness of breath or uncontrolled pain >3/10.
- Uncontrolled hypertension or diabetes.
- Bone fracture in the past 6 months.
- Disability limiting activities of daily living.
- History of epilepsy or uncontrolled seizures in past year.
- Sedative medication use that may interfere with training.
- Use of Alzheimer's/dementia-modifying drugs or enrollment in AD clinical trials.
- Use of antidepressants or anxiety medications.
- Moderate or high risk on PAR-Q (≤1 "yes" response).
- Severe cognitive impairment (TICS-M ≥18).
- Currently receiving cognitive or physical rehabilitation.
- Pacemaker use.
Initial Screening Exclusion Criteria:
- Cardiovascular parameters outside safety limits (HR, BP, O₂ saturation).
- Global aphasia (Mississippi <71 percent).
- Peripheral nerve injury.
- Berg Balance Scale <40/56.
- Inability to walk one block with or without an assistive device.
Population Exclusions:
- Non-English speakers (protocol delivered only in English).
- Individuals under 18 years.
- Pregnant individuals.
- Prisoners or other vulnerable populations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Group
Participants assigned to the Functional Balance Intervention (FBI) will complete a 4 month, home based, multicomponent balance and cognitive motor training program.
Sessions occur 2 days per week for 1 hour each and are performed independently at home with a designated helper buddy present for safety.
Each session includes randomized blocks of functional agility, functional strength, dual task cognitive motor exercises, and vestibular training.
Exercises emphasize dynamic balance, multi joint strength, postural control, attention, processing speed, and visuospatial orientation.
Dual task components include custom computer based stepping games that integrate cognitive tasks with functional movements.
Vestibular components include gaze stabilization, head turn walking, and figure of eight walking.
Exercise difficulty progresses based on predefined home evaluation criteria.
Participants receive a training manual, home equipment kit, weekly follow up via Zoom, and safety monitoring.
|
The Functional Balance Intervention (FBI) is a multicomponent, home based cognitive motor training program designed specifically for persons with Multiple Sclerosis.
It integrates four structured constructs-functional agility, functional strength, dual task cognitive motor exercises, and vestibular training-within each 1 hour session.
The program uses custom designed interactive dual task stepping games that require simultaneous motor stepping responses and cognitive tasks such as arithmetic, category fluency, and visuospatial cue discrimination.
Vestibular components include gaze stabilization, head turn walking, and figure of eight patterns.
Progression is individualized using predefined home evaluation criteria (step count, chair stands, tandem stance, single leg stance, and perceived stability).
Training is completed independently at home with a helper buddy present and supported by weekly Zoom sessions.
|
|
Active Comparator: Stretching Group
Participants assigned to the stretching program will complete a 4 month, home based flexibility training regimen matched in duration and frequency to the intervention group.
Sessions occur 2 days per week for 1 hour each and include progressive stretching of major upper limb, lower limb, core, and back muscle groups.
All stretches are performed in standing to match upright time and positional demands of the Functional Balance Intervention.
Each session begins with a brief warm up and concludes with a 10 minute cool down emphasizing relaxation and breathing exercises.
Participants receive a printed exercise manual detailing weekly schedules, safety precautions, and instructions for each stretch.
No specialized equipment or computer based components are required.
A helper buddy must remain present during all sessions for safety.
Participants also participate in weekly Zoom check ins to monitor adherence, address concerns, and review home safety recommendations.
|
The stretching program is a non-progressive, home based flexibility protocol designed to serve as an active control condition.
Unlike the Functional Balance Intervention, this program does not include agility, strength, dual task, vestibular, or cognitive motor components, and it does not use computerized games or progressive home evaluations.
Participants complete 1 hour sessions, 2 days per week for 4 months, consisting solely of static stretches targeting major upper extremity, lower extremity, trunk, and back muscle groups.
All stretches are performed in standing to match the positional demands and session duration of the experimental arm without engaging balance or cognitive systems.
The program emphasizes gentle range of motion, posture, breathing, and relaxation rather than neuromotor challenge.
No equipment is required beyond the printed stretching manual, and exercises do not progress in complexity or intensity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety: occurrence of adverse events
Time Frame: Last week of training (Month 4)
|
Non-serious adverse events may include transient muscle soreness, fatigue, mild dizziness, temporary loss of balance corrected by the helper buddy, or minor joint discomfort during home exercise. These events do not require medical intervention and are reported during weekly check ins or directly to study staff. Serious adverse events include any event resulting in injury requiring medical care, hospitalization, life-threatening symptoms, severe cardiovascular responses (chest pain, uncontrolled shortness of breath, hypertensive crisis), oxygen desaturation below safety thresholds, or falls causing significant injury. The helper buddy is instructed to stop activity immediately, call emergency services when necessary, and notify the research team. All adverse events are monitored throughout screening, assessments, and training sessions, and are reviewed by the PI with prompt IRB reporting as required. |
Last week of training (Month 4)
|
|
Adherence
Time Frame: End of training (Month 4)
|
Adherence will be monitored by tracking completion of all scheduled home training sessions, weekly Zoom check ins, and timely completion of progression evaluations and questionnaires.
Participants are expected to complete 2 sessions per week for 4 months, and adherence will be defined as completing at least 75 percent of planned sessions.
Attendance logs, helper buddy confirmation, and participant self reports are reviewed weekly by study staff to document adherence and address barriers to participation.
|
End of training (Month 4)
|
|
Change in Physical Function measured by Short Physical Performance Battery
Time Frame: Baseline, 1 week post-training
|
The Short Physical Performance Battery (SPPB) is a validated measure of lower extremity physical function that includes three components: standing balance, gait speed, and repeated chair stands.
Balance is assessed using side by side, semi tandem, and tandem stances; gait speed is measured over a short walking distance; and strength/mobility is evaluated using five repeated chair rises.
Scores from each component are combined into a 0-12 total score, with higher scores indicating better physical function.
For this study, the SPPB is administered remotely over Zoom with camera positioning and helper buddy support to ensure safety during all standing and mobility tasks.
|
Baseline, 1 week post-training
|
|
Change in Walking Function: Dynamic Gait Index (DGI)
Time Frame: Baseline, 1 week post-training
|
The Dynamic Gait Index (DGI) is a clinical measure of functional gait performance that assesses an individual's ability to adapt walking to varying task demands.
The test includes eight walking tasks such as changing gait speed, head turns, pivot turns, stepping over obstacles, and stair climbing.
Each task is scored on a 0-3 scale, with a maximum total score of 24; higher scores indicate better dynamic gait stability.
In this study, the DGI is administered remotely with helper buddy supervision to ensure safety during all gait tasks.
|
Baseline, 1 week post-training
|
|
Change in Walking endurance: Timed 25-Foot Walk
Time Frame: Baseline, 1 week post-training
|
The Timed 25-Foot Walk is a standardized measure of gait speed and lower extremity mobility in persons with neurological conditions.
Participants are instructed to walk 25 feet as quickly and safely as possible, and the time to complete the distance is recorded in seconds.
Faster times indicate better ambulatory function.
In this study, the Timed-25 Foot Walk is administered remotely over Zoom with appropriate camera positioning and helper buddy supervision to ensure safety during the walking task.
|
Baseline, 1 week post-training
|
|
Change in information processing speed
Time Frame: Baseline, 1 week post-training
|
The Symbol Digit Modalities Test evaluates information processing speed, attention, and visual scanning.
Participants are shown a key that pairs simple symbols with numbers and are asked to verbally report the number corresponding to each symbol presented on the screen as quickly and accurately as possible within a fixed time period.
The test takes approximately 5 minutes to complete.
The Symbol Digits Modalities score is calculated as the total number of correct symbol-number pairings completed within the time limit, with scores typically ranging from 0 to approximately 110.
Higher scores indicate faster processing speed and better performance, while lower scores reflect greater difficulty with information processing.
|
Baseline, 1 week post-training
|
|
Change in verbal learning and memory
Time Frame: Baseline, 1 week post-training
|
The California Verbal Learning Test-II assesses verbal learning and memory.
Participants hear a list of words read aloud by the examiner and are asked to recall as many words as possible immediately after each presentation.
This procedure is repeated across five learning trials using the same word list.
The task takes approximately 7-10 minutes.
The score used for BICAMS is the total number of words correctly recalled across the five learning trials, with possible scores ranging from 0 to 80. Higher scores indicate better verbal learning and memory, while lower scores indicate greater difficulty with learning and recalling verbal information.
|
Baseline, 1 week post-training
|
|
Change in visuospatial learning and memory
Time Frame: Baseline, 1 week post-training
|
The Brief Visuospatial Memory Test-Revised evaluates visuospatial learning and memory.
Participants are briefly shown a display of simple geometric figures arranged in a specific pattern.
After the figures are removed, participants are asked to reproduce the figures and their locations from memory.
This process is repeated across three learning trials and takes approximately 5 minutes.
The Brief Visuospatial Memory Test-Revised score used for Brief International Cognitive Assessment for Multiple Sclerosis is the total recall score across the three trials, with possible scores ranging from 0 to 36.
Higher scores indicate better visuospatial learning and memory, while lower scores reflect greater visuospatial memory impairment.
|
Baseline, 1 week post-training
|
|
Change in Dual-task balance cost
Time Frame: Baseline, 1 week post-training
|
Dual-Task Balance Cost (Limits of Stability + Letter-Number Sequencing) Dual-task balance cost is assessed by combining the Limits of Stability test with a concurrent Letter-Number Sequencing task.
Participants perform controlled reaching movements in multiple directions while simultaneously generating an alternating number-letter sequence.
Balance performance (reach distance and control) and cognitive accuracy are recorded under both single-task and dual-task conditions.
Dual-task cost is calculated as the relative change in balance performance when the cognitive task is added.
This assessment is conducted remotely over Zoom with helper buddy supervision for safety.
|
Baseline, 1 week post-training
|
|
Change in Community Mobility: University of Alabama Birmingham (UAB) Questionnaire
Time Frame: Baseline, 1 week post-training
|
The Life-Space Questionnaire assesses real-world community mobility by capturing how far and how often a person moves through different life-space levels, ranging from within the home to travel outside the local community.
Scores reflect the frequency, independence, and distance of mobility over the past four weeks, with higher scores indicating greater community mobility.
In this study, the questionnaire is completed remotely via REDCap or Zoom based on participant preference.
|
Baseline, 1 week post-training
|
|
Change in Community Mobility: Accelerometer
Time Frame: Baseline, 1 week post-training
|
Community mobility is objectively measured using a wearable ActiGraph accelerometer worn for 7 consecutive days for at least 12 hours per day.
The device captures step counts, activity levels, and movement patterns that reflect real-world mobility outside the laboratory or home.
Data are downloaded and analyzed to quantify overall mobility and time spent in different activity intensities.
Participants receive the device by mail and return it using a prepaid shipping label.
|
Baseline, 1 week post-training
|
|
Change in Quality of Life: Multiple Sclerosis Impact Scale (MSIS-29)
Time Frame: Baseline, 1 week post-training
|
Quality of life is assessed using the Multiple Sclerosis Impact Scale (MSIS-29), a validated self-report questionnaire measuring the physical (20 items) and psychological (9 items) impact of MS on daily functioning.
Scores reflect the extent to which MS affects mobility, activities, mood, and overall well-being, with higher scores indicating greater impact.
The MSIS-29 is completed remotely via REDCap or during a Zoom session based on participant preference.
|
Baseline, 1 week post-training
|
|
Change in Balance Confidence: Activities-Specific Balance Confidence (ABC)
Time Frame: Baseline, 1 week post-training
|
Balance confidence is measured using the Activities-Specific Balance Confidence (ABC) Scale, a validated 16-item questionnaire assessing an individual's confidence in performing common daily activities without losing balance.
Participants rate their confidence from 0 to 100 percent for each activity, with higher scores indicating greater balance self-efficacy.
The ABC Scale is completed remotely via REDCap or during a Zoom session according to participant preference.
|
Baseline, 1 week post-training
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Motl RW, Sandroff BM, Kwakkel G, Dalgas U, Feinstein A, Heesen C, Feys P, Thompson AJ. Exercise in patients with multiple sclerosis. Lancet Neurol. 2017 Oct;16(10):848-856. doi: 10.1016/S1474-4422(17)30281-8. Epub 2017 Sep 12.
- Tramontano M, Martino Cinnera A, Manzari L, Tozzi FF, Caltagirone C, Morone G, Pompa A, Grasso MG. Vestibular rehabilitation has positive effects on balance, fatigue and activities of daily living in highly disabled multiple sclerosis people: A preliminary randomized controlled trial. Restor Neurol Neurosci. 2018;36(6):709-718. doi: 10.3233/RNN-180850.
- DeLuca J, Chiaravalloti ND, Sandroff BM. Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nat Rev Neurol. 2020 Jun;16(6):319-332. doi: 10.1038/s41582-020-0355-1. Epub 2020 May 5.
- Kannan L, Vora J, Bhatt T, Hughes SL. Cognitive-motor exergaming for reducing fall risk in people with chronic stroke: A randomized controlled trial. NeuroRehabilitation. 2019;44(4):493-510. doi: 10.3233/NRE-182683.
- Veldkamp R, Baert I, Kalron A, Tacchino A, D'hooge M, Vanzeir E, Van Geel F, Raats J, Goetschalckx M, Brichetto G, Shalmoni N, Hellinckx P, De Weerdt N, De Wilde D, Feys P. Structured Cognitive-Motor Dual Task Training Compared to Single Mobility Training in Persons with Multiple Sclerosis, a Multicenter RCT. J Clin Med. 2019 Dec 10;8(12):2177. doi: 10.3390/jcm8122177.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Mental Disorders
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Autoimmune Diseases
- Immune System Diseases
- Neurocognitive Disorders
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Cognition Disorders
- Pathological Conditions, Signs and Symptoms
- Multiple Sclerosis
- Cognitive Dysfunction
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Chronic Progressive
Other Study ID Numbers
- 2025-0796
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States